{"id":"https://openalex.org/W2518800810","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.7607","title":"Use of germline polymorphisms in VEGF to predict tumor response and progression-free survival in non-small cell lung cancer (NSCLC) patients treated with sorafenib: Subset pharmacogenetic analysis of Eastern Cooperative Oncology Group (ECOG) trial E2501.","display_name":"Use of germline polymorphisms in VEGF to predict tumor response and progression-free survival in non-small cell lung cancer (NSCLC) patients treated with sorafenib: Subset pharmacogenetic analysis of Eastern Cooperative Oncology Group (ECOG) trial E2501.","publication_year":2010,"publication_date":"2010-05-20","ids":{"openalex":"https://openalex.org/W2518800810","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.7607","mag":"2518800810"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2010.28.15_suppl.7607","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.7607","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.7607","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5048866618","display_name":"W. Zhang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. Zhang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079028586","display_name":"J. Lee","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Lee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050185260","display_name":"Joan H. Schiller","orcid":"https://orcid.org/0000-0003-0990-1211","observed_orcids":["https://orcid.org/0000-0003-0990-1211"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. H. Schiller","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059652753","display_name":"David Paul Carbone","orcid":"https://orcid.org/0000-0003-3002-1921","observed_orcids":["https://orcid.org/0000-0003-3002-1921"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. P. Carbone","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016127308","display_name":"Christine H. Chung","orcid":"https://orcid.org/0000-0001-5199-4306","observed_orcids":["https://orcid.org/0000-0001-5199-4306"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. H. Chung","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5108487718","display_name":"Heinz Joseph Lenz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. Lenz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"28","issue":"15_suppl","first_page":"7607","last_page":"7607"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9560999870300293,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9560999870300293,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.025299999862909317,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.012299999594688416,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vegf-polymorphisms","display_name":"VEGF polymorphisms","score":0.8130000233650208},{"id":"https://openalex.org/keywords/sorafenib","display_name":"sorafenib","score":0.7910000085830688},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9860000014305115},{"id":"https://openalex.org/keywords/pharmacogenetics","display_name":"pharmacogenetics","score":0.9269999861717224},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7279999852180481},{"id":"https://openalex.org/keywords/tumor-response","display_name":"tumor response","score":0.7549999952316284},{"id":"https://openalex.org/keywords/anti-vegf-therapy","display_name":"anti-VEGF therapy","score":0.7300000190734863},{"id":"https://openalex.org/keywords/metastatic-nsclc","display_name":"metastatic non-small cell lung cancer","score":0.7549999952316284},{"id":"https://openalex.org/keywords/disease-control-rate","display_name":"disease control rate","score":0.746999979019165},{"id":"https://openalex.org/keywords/angiogenesis-related-genes","display_name":"angiogenesis-related genes","score":0.6290000081062317},{"id":"https://openalex.org/keywords/egfr","display_name":"EGFR","score":0.6850000023841858},{"id":"https://openalex.org/keywords/interleukin-8","display_name":"interleukin-8","score":0.6869999766349792}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8545635938644409},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7617727518081665},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6612592935562134},{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.6303645372390747},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5631198883056641},{"id":"https://openalex.org/C135763542","wikidata":"https://www.wikidata.org/wiki/Q106016","display_name":"Genotype","level":3,"score":0.5429754257202148},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.53058260679245},{"id":"https://openalex.org/C2780394083","wikidata":"https://www.wikidata.org/wiki/Q539568","display_name":"Angiogenesis","level":2,"score":0.41821396350860596},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4098402261734009},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3630916178226471},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.2245904505252838},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0823616087436676},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2010.28.15_suppl.7607","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.7607","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.7607","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2120243407","https://openalex.org/W4400492624","https://openalex.org/W4220963420","https://openalex.org/W2082853217","https://openalex.org/W2018670837","https://openalex.org/W2943156946","https://openalex.org/W2410630313","https://openalex.org/W2131209749","https://openalex.org/W2250055160","https://openalex.org/W2117087331"],"abstract_inverted_index":{"7607":[0],"Background:":[1],"E2501":[2],"was":[3],"a":[4,212],"randomized":[5,127],"discontinuation":[6],"phase":[7],"II":[8],"study":[9],"of":[10,92,144,207],"sorafenib":[11],"(S)":[12],"versus":[13],"placebo":[14],"(P)":[15],"in":[16,48,78,81,231,344,351],"patients":[17,79],"(pts)":[18],"with":[19,37,120,175,192,216,251,268,283,299,315,355],"metastatic":[20],"NSCLC":[21,55,352],"who":[22],"have":[23,260],"failed":[24],"at":[25],"least":[26],"two":[27],"prior":[28],"chemotherapy":[29],"regimens.":[30],"Recent":[31],"studies":[32],"suggested":[33],"that":[34,62],"polymorphisms":[35,64,343],"associated":[36],"angiogenesis":[38],"pathway":[39],"can":[40],"predict":[41,75,347],"clinical":[42,76],"outcome":[43,77],"to":[44,128,259,360],"anti-VEGF":[45],"based":[46],"therapies":[47],"advanced":[49,54],"breast":[50],"cancer":[51],"(E2100)":[52],"and":[53,118,161,166,226,240,349],"(E4599)":[56],"pts.":[57],"We":[58],"tested":[59],"the":[60,334],"hypothesis":[61],"gene":[63],"(VEGF,":[65],"EGF,":[66],"EGFR,":[67],"IL-8,":[68],"CXCR2,":[69],"COX-2,":[70],"KDR,":[71],"ICAM1,":[72],"FGFR4)":[73],"may":[74,346],"enrolled":[80],"E2501.":[82],"Methods:":[83],"During":[84],"Step":[85,108,159,171,247],"1,":[86],"333":[87],"pts":[88,103,114,119,157,353],"received":[89],"400":[90],"mg":[91],"S":[93,131,165,250],"po":[94],"twice":[95],"daily":[96],"for":[97,152,178],"2":[98,248],"cycles":[99],"(2":[100],"months).":[101],"Responding":[102],"(n":[104,123,187,195,253,272,291,302,318],"=":[105,124,188,196,200,223,238,242,254,264,273,276,280,292,295,303,306,310,319,322,326],"12)":[106],"on":[107,111,138,164,168,246],"1":[109,160],"continued":[110],"S;":[112],"progressing":[113],"went":[115],"off":[116],"study,":[117],"stable":[121],"disease":[122,183],"107)":[125],"were":[126,136,147,331],"P":[129],"or":[130,369,373],"(Step":[132],"2).":[133],"PCR-RFLP":[134],"assays":[135],"performed":[137],"genomic":[139],"DNA":[140],"extracted":[141],"from":[142,158,170],"plasma":[143,149],"patients.":[145],"There":[146],"88":[148],"samples":[150],"available":[151],"analysis:":[153],"these":[154,362],"included":[155],"76":[156],"18":[162],"(14":[163],"4":[167],"P)":[169],"2.":[172],"Results:":[173],"Patients":[174,202,245,282],"CC":[176,270,285],"genotype":[177,194,218,271,286,301,317],"VEGF1498":[179,227,284],"had":[180,211,287],"significantly":[181,288],"lower":[182],"control":[184],"rate":[185],"(DCR)":[186],"22,":[189],"22.7%)":[190],"compared":[191,215,267,298],"TT":[193,217,316],"25,":[197],"56%),":[198],"(p":[199,222,237,279,309,325],"0.036).":[201],"harboring":[203],"any":[204],"C":[205],"allele":[206],"VEGF":[208,345],"1498":[209],"(CC+CT)":[210],"worse":[213],"DCR":[214,348],"(26%":[219],"vs":[220],"56%)":[221],"0.021).":[224],"VEGF634":[225,256,269],"showed":[228],"significant":[229,329],"differences":[230,330],"PFS":[232,262,290,350],"among":[233,333],"their":[234],"three":[235],"genotypes":[236,257],"0.036":[239],"p":[241],"0.025,":[243],"respectively).":[244],"receiving":[249],"GG/GC":[252],"6/4)":[255],"tended":[258],"shorter":[261],"(median":[263],"1.7-2.8":[265],"mos)":[266,278,297,308,324],"2,":[274,304],"median":[275,294,305,321],"7.7":[277],"0.23).":[281],"longer":[289],"4,":[293],"7.5":[296],"CT":[300],"1.7":[307],"0.018),":[311],"but":[312],"no":[313],"difference":[314],"7,":[320],"2.8":[323],"0.60).":[327],"No":[328],"observed":[332],"other":[335],"genes":[336],"tested.":[337],"Conclusions:":[338],"Our":[339],"preliminary":[340],"results":[341],"suggest":[342],"treated":[354],"sorafenib.":[356],"Larger":[357],"prospective":[358],"trials":[359],"validate":[361],"findings":[363],"are":[364],"warranted.":[365],"Author":[366],"Disclosure":[367],"Employment":[368],"Leadership":[370],"Position":[371],"Consultant":[372],"Advisory":[374],"Role":[375],"Stock":[376],"Ownership":[377],"Honoraria":[378],"Research":[379],"Funding":[380],"Expert":[381],"Testimony":[382],"Other":[383],"Remuneration":[384],"Bayer":[385,386]},"counts_by_year":[{"year":2014,"cited_by_count":1},{"year":2012,"cited_by_count":2}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2016-09-23T00:00:00"}